reports
Stitch Fix Announces Third Quarter of Fiscal Year 2025 Financial Resul...
Stitch Fix Announces Third Quarter of Fiscal Year 2025 Financial Results SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ: SFIX), the leading online personal styling service, today announced its financial results for the third quarter of fiscal year 2025, ended May 3, 2025. “Stitch Fix delivered strong third quarter results, marked by our overall return to year-over-year revenue growth,” said Matt Baer, CEO, Stitch Fix. “Our performance, which exceeded expectations, is the direct result of the strength of the Stitch Fix value proposition and the team's discipline...
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units coveri...
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for ...
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair Based on market research, inguinal hernia repair is the most common type of hernia repair MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. T...
TELA Bio Appoints Jeffrey Blizard as President
TELA Bio Appoints Jeffrey Blizard as President Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio’s Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. “...
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Confer...
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA’s management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, Inc.TELA Bio, ...
Stitch Fix Announces Date for Third Quarter 2025 Financial Results and...
Stitch Fix Announces Date for Third Quarter 2025 Financial Results and Conference Call SAN FRANCISCO, May 20, 2025 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ:SFIX), the leading online personal styling service, today announced that it will release financial results for its third quarter fiscal year 2025 ended May 3, 2025 after market close on Tuesday, June 10, 2025. Following this, Stitch Fix will hold a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results and outlook. The call will be hosted by Matt Baer, CEO, and David Aufderhaar, CFO. A live webcast of the ...
CPS Announces First Quarter 2025 Earnings
CPS Announces First Quarter 2025 Earnings Revenues of $106.9 million compared to $91.7 million in the prior year periodNet income of $4.7 million, or $0.19 per diluted shareTotal portfolio balance of $3.615 billion, highest in company historyNew contract purchases of $451.2 million LAS VEGAS, NV, May 12, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.7 million, or $0.19 per diluted share, for its first quarter ended March 31, 2025. This compares to a net income of $4.6 million, or $0.19 per diluted share, ...
CPS Announces $419.95 Million Senior Subordinate Asset-Backed Securiti...
CPS Announces $419.95 Million Senior Subordinate Asset-Backed Securitization LAS VEGAS, Nevada, May 12, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) announced the closing of its second term securitization in 2025 on Monday May 12, 2025. The transaction is CPS's 55th senior subordinate securitization since the beginning of 2011 and the 38th consecutive securitization to receive a triple “A” rating from at least two rating agencies on the senior class of notes. In the transaction, qualified institutional buyers purchased $419....
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuan...
CPS to Host Conference Call on First Quarter 2025 Earnings
CPS to Host Conference Call on First Quarter 2025 Earnings Las Vegas, Nevada, May 09, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it will hold a conference call on Tuesday, May 13, 2025 at 1:00 p.m. ET to discuss its first quarter 2025 operating results. Those wishing to participate can pre-register for the conference call at the following link . Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the confere...
TELA Bio Reports First Quarter 2025 Financial Results
TELA Bio Reports First Quarter 2025 Financial Results MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix product...
Consumer Portfolio Services Deploys AI-Powered Servicing Platform from...
Consumer Portfolio Services Deploys AI-Powered Servicing Platform from Salient to Advance Collections Strategy LAS VEGAS, NV, May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CPSS) (“CPS” or the “Company”), a leader in providing indirect automobile financing to consumers, today announced the deployment of a next-generation AI-powered servicing and collections platform developed in partnership with Salient, a leading provider of AI voice agent solutions tailored for the automotive industry. As Consumer Portfolio Services continues to scale its loan portfolio and optimize servicing operations, S...
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent ...
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights – Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, May 01, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-med...
TELA Bio to Announce First Quarter 2025 Financial Results
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham ...
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® P...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic...
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Resu...
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights – Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism – – SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – – Cash balance of approximately $73.0 million as of D...
CPS Announces $65.0 Million Securitization of Residual Interests
CPS Announces $65.0 Million Securitization of Residual Interests LAS VEGAS, Nevada, March 20, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $65.0 million securitization of residual interests from previously issued securitizations. In the transaction, a qualified institutional buyer purchased $65.0 million of asset-backed notes secured by an 80% interest in a CPS majority owned affiliate (“MOA”) that owns the residual interests in five CPS securitizations issued from October 2023 through September 2024. ...
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for O...
Stitch Fix Announces Second Quarter of Fiscal Year 2025 Financial Resu...
Stitch Fix Announces Second Quarter of Fiscal Year 2025 Financial Results SAN FRANCISCO, March 11, 2025 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ: SFIX), the leading online personal styling service, today announced its financial results for the second quarter of fiscal year 2025, ended February 1, 2025. “Our team delivered another strong quarter, once again exceeding our expectations as we further advanced our transformation strategy,” said Matt Baer, CEO, Stitch Fix. “Our clients are responding to the improvements we’ve made to our experience, including the increased newness in our a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.